New clotting factor shows promise for hemophilia a bleeds

NCT ID NCT06297655

Ongoing Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests a lab-made clotting factor VIII in 60 people with severe hemophilia A. The treatment is given on-demand for new bleeding episodes or before surgery. The goal is to see if it safely and effectively stops bleeding and supports surgical recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: recombinant human coagulation factor VIII
What this could lead to: If successful, this could provide a safe and effective on-demand treatment option for bleeding episodes and surgical support in severe hemophilia A.
What could go wrong: This is a single-arm, open-label trial with only 60 participants, so results may not be generalizable. The treatment is not a cure and requires ongoing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A severe hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A

Contacts and locations

Locations

Anhui Provincial Hospital

Hefei, Anhui, 230002, China
Fuyang Hospital Affiliated to Anhui Medical University

Fuyang, Anhui, 236000, China
Hematology Hospital of Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, 300020, China
Henan Tumor Hospital

Zhengzhou, Henan, 450003, China
Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, 330006, China
Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, 510515, China
Nanjing Drug Tower Hospital

Nanjing, Jiangsu, 210008, China
The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, 530021, China
The First Hospital of Lanzhou University

Lanzhou, Gansu, 730013, China
The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400010, China
The Second Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, 650106, China
Xiangya Hospital Central South University

Changsha, Hunan, 410008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.